Bank of America Corporation Cuts GW Pharmaceuticals PLC (GWPH) Price Target to $158.00

GW Pharmaceuticals PLC (NASDAQ:GWPH) had its price objective cut by Bank of America Corporation from $160.00 to $158.00 in a report issued on Tuesday morning. They currently have a buy rating on the biopharmaceutical company’s stock.

GWPH has been the topic of a number of other reports. Goldman Sachs Group, Inc. (The) reiterated a neutral rating and set a $124.00 price target on shares of GW Pharmaceuticals PLC in a research note on Friday, October 6th. Zacks Investment Research lowered shares of GW Pharmaceuticals PLC from a buy rating to a hold rating in a research note on Monday, July 24th. ValuEngine upgraded shares of GW Pharmaceuticals PLC from a sell rating to a hold rating in a research note on Friday, September 1st. Evercore ISI started coverage on shares of GW Pharmaceuticals PLC in a research note on Wednesday, August 16th. They set an outperform rating and a $154.00 price target on the stock. Finally, Cantor Fitzgerald set a $208.00 price target on shares of GW Pharmaceuticals PLC and gave the stock a buy rating in a research note on Tuesday, August 8th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of Buy and an average target price of $144.55.

Shares of GW Pharmaceuticals PLC (NASDAQ GWPH) traded down $1.67 during trading on Tuesday, hitting $115.88. 355,541 shares of the stock were exchanged, compared to its average volume of 319,149. GW Pharmaceuticals PLC has a twelve month low of $92.65 and a twelve month high of $136.95. The company has a current ratio of 10.39, a quick ratio of 10.26 and a debt-to-equity ratio of 0.02.

WARNING: “Bank of America Corporation Cuts GW Pharmaceuticals PLC (GWPH) Price Target to $158.00” was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this article on another publication, it was illegally stolen and republished in violation of US and international copyright and trademark laws. The original version of this article can be viewed at https://ledgergazette.com/2017/11/17/bank-of-america-corporation-cuts-gw-pharmaceuticals-plc-gwph-price-target-to-158-00.html.

Several institutional investors and hedge funds have recently made changes to their positions in GWPH. IHT Wealth Management LLC lifted its stake in shares of GW Pharmaceuticals PLC by 18.0% during the second quarter. IHT Wealth Management LLC now owns 656 shares of the biopharmaceutical company’s stock valued at $108,000 after buying an additional 100 shares during the period. Advisor Group Inc. lifted its stake in shares of GW Pharmaceuticals PLC by 10.7% during the second quarter. Advisor Group Inc. now owns 1,500 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 145 shares during the period. BNP Paribas Arbitrage SA purchased a new position in shares of GW Pharmaceuticals PLC during the second quarter valued at approximately $163,000. Woodmont Investment Counsel LLC purchased a new position in shares of GW Pharmaceuticals PLC during the second quarter valued at approximately $201,000. Finally, Quantitative Systematic Strategies LLC purchased a new position in shares of GW Pharmaceuticals PLC during the second quarter valued at approximately $204,000. 75.71% of the stock is currently owned by institutional investors and hedge funds.

GW Pharmaceuticals PLC Company Profile

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).

Analyst Recommendations for GW Pharmaceuticals PLC (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply